Drug-perturbation-based stratification of blood cancer

Journal: Journal of Clinical Investigation

Published: 2018-01-02

DOI: 10.1172/jci93801

Affiliations: 30

Authors: 51

Go to article
Institutions FC
National Center for Tumor Diseases (NCT) Heidelberg, Germany 0.26
European Molecular Biology Laboratory (EMBL), Germany 0.17
Department of Internal Medicine V: Hematology, Oncology and Rheumatology, Uni Heidelberg, Germany 0.07
Department of Molecular Medicine and Surgery (MMK), KI, Sweden 0.06
German Consortium of Translational Cancer Research (DKTK), Germany 0.05
Cellzome GmbH, Germany 0.04
Hematology Research Unit Helsinki, Finland 0.04
Division of Biostatistics, DKFZ, Germany 0.04
EMBL Chemical Biology Core Facility, Germany 0.04
Department of Haematology, University of Cambridge, United Kingdom (UK) 0.02
Division of Molecular Genetics, DKFZ, Germany 0.02
Mannheim Oncology Practice, Germany 0.02
Klinik I für Innere Medizin, UoC, Germany 0.02
Chair of Organic Chemistry II, FAU, Germany 0.02
Institute of Human Genetics, Uni Heidelberg, Germany 0.02
Division of Epigenomics and Cancer Risk Factors, DKFZ, Germany 0.02
Molecular Medicine Partnership Unit (MMPU), Germany 0.01
Dipartimento di Medicina Traslazionale, UNIPMN, Italy 0.01
Oncology Institute of Southern Switzerland (IOSI), Switzerland 0.01
Department of Medicine I: Hematology, Oncology, and Stem-Cell Transplantation, Uni Freiburg, Germany 0.01
Cordelier Research Center (CRC), France 0.01
AP-HP Pitié-Salpêtrière Hospital - Charles-Foix, France 0.01
Clinic for Hematology, UDE, Germany 0.01
OSU Department of Biomedical Informatics (BMI), United States of America (USA) 0.01
Heidelberg Center for Personalized Oncology (HIPO), NCT, Germany 0.01
OSU Division of Hematology, United States of America (USA) 0.01
Cambridge Institute for Medical Research (CIMR), University of Cambridge, United Kingdom (UK) 0
Department of Medicine II, GU, Germany 0
Department of Hematology, UZH, Switzerland 0